Pfizer announced November 18th that the biosimilar licensing application (BLA) for its adalimumab biosimilar was approved by the Food and Drug Administration (FDA). The drug will be marketed under the name Abrilada™ (adalimumab-afzb) in November 2023, according to the terms of a licensing agreement with AbbVie.    According to Pfizer, the drug was approved for … Continue reading Pfizer Reaches Milestone: FDA Approves 25th Biosimilar in US →